Ali Maleki

Ali Maleki

Auto-generated profile, based on publicly available information

Ali Maleki

COVID-19 National Reference Laboratory (CNRL), Pasteur Institute of Iran, Tehran, Iran

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 January 2022 in Archives of Virology
Verified
Journal Article
Closed access
PDF file
MSMostafa Salehi-Vaziri
Mostafa Salehi-Vaziri
MFMehdi Fazlalipour
Mehdi Fazlalipour
SKSeyed Mahmood Seyed Khorrami
Seyed Mahmood Seyed Khorrami
KAKayhan Azadmanesh
Kayhan Azadmanesh
MPMohammad Hassan Pouriayevali
Mohammad Hassan Pouriayevali
AMAli Maleki
Ali Maleki

14 February 2022 in Intervirology
Verified
Journal Article
Open access
PDF file
RKRoya Kianfar
Roya Kianfar
MRMehrdad Ravanshad
Mehrdad Ravanshad
MGMohammad Adel Ghiass
Mohammad Adel Ghiass
NRNastaran Rafiee
Nastaran Rafiee
ASAli Shayeghpour
Ali Shayeghpour
AMAli Maleki
Ali Maleki
Introduction: Epstein-Barr virus (EBV/HHV-4) has been implicated in the pathogenesis of multiple sclerosis (MS). This study was conducted to investigate the levels of pro-inflammatory cytokines IL-1β and IL-6 in healthy EBV carriers and MS patients with prior EBV infection in response to treatment with EBV nuclear antigen 1 (EBNA-1) and replication and transcription activator (BRLF-1/Rta) peptide antigens in whole blood cell culture to assess the cytokine expression across all cells in the peripheral blood. Methods: Isolated whole blood cells from the included participants were incubated at a concentration of 106 cells/mL with BRLF-1 or EBNA-1. The amount of IL-1β and IL-6 transcripts were measured with quantitative RT-PCR at day 3 after incubation. MTT assay was conducted to examine cytotoxicity of the peptides and their effect on cell viability. Changes in cytokine expression and cell viability were analyzed using one-way and two-way ANOVA, respectively. Results: Ten MS patients and ten healthy donors were enrolled in the study. Treatment with the peptide antigens resulted in increased cytokines expression in both MS patients and healthy subjects. Furthermore, IL-1β levels were higher in MS patients compared to healthy EBV carriers. MTT assay revealed no significant difference in cell viability between the two groups. Discussion: The higher levels of IL-1β in response to EBV antigens in MS patients may reflect the host neuroinflammatory environment and support the notion that immune response against EBV has a role as an aggravating factor in the progression of MS by contributing to the neuroinflammatory cascade.

25 June 2021 in Intervirology
Verified
Journal Article
Closed access
PDF file
NRNastaran Rafiee
Nastaran Rafiee
MRMehrdad Ravanshad
Mehrdad Ravanshad
BABahador Asadi
Bahador Asadi
RKRoya Kianfar
Roya Kianfar
AMAli Maleki
Ali Maleki
Introduction: Epstein-Barr virus (EBV), a double-stranded DNA virus, has 2 phases of lytic and latent infection in host cells. After infecting B lymphocytes, EBV becomes persistent in these cells. In healthy individuals, T lymphocytes play a key role in killing EBV-infected B cells. Statistical studies have shown that symptomatic EBV infection increases the risk of MS. Methods: This study intended to measure the immune system’s response against the different components of EBV, focusing particularly on T lymphocytes’ reaction. Consequently, the mRNA level of IL-2 and IFN-γ, liable for impressing autoimmune diseases and as indicators of T-cell function, was compared in EBNA1- and BRLF1-treated whole blood (WB) cultures of 10 healthy individuals and 10 MS patients using real-time RT-PCR. Results: The analysis of the results demonstrated a significant increased level of IL-2 in MS patients than healthy subjects after exposure to both peptides. Also, the mRNA level of IFN-γ increased in MS patients in EBNA1-treated WB culture. Conclusion: According to the study’s results, EBV peptides can reactivate immune cells, especially T lymphocytes, and may indirectly induce inflammation and develop MS; however, it seems that long-time exposure to these peptides has reducing effect on T-cell function and faces the control of infected B lymphocytes with difficulties.

30 July 2024 in Letters in Applied Microbiology
Verified
Journal Article
Open access
PDF file
BKBardia Karim
Bardia Karim
MBMohammad Barary
Mohammad Barary
ZFZahra Fereydouni
Zahra Fereydouni
ESElaheh Sanjari
Elaheh Sanjari
RHRezvan Hosseinzadeh
Rezvan Hosseinzadeh
AMAli Maleki
Ali Maleki
Since the emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), new variants with enhanced transmissibility and pathogenicity have surfaced. The World Health Organization has designated five such variants—Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), Delta (B.1.617.2), and Omicron (B.1.1.529)—as variants of concern. Each variant exhibits distinct characteristics, with many displaying a combination of point mutations and insertions/deletions (indels). These genetic alterations, including mutations, recombinations, and rearrangements, contribute to the emergence of new strains that may exhibit modified phenotypes. However, identifying recombinant forms can be challenging due to their resemblance to other lineages. It is critical to monitor the evolution of new recombinant variants, particularly in light of the potential for vaccine-resistant strains and their accelerated propagation. Recombination has played a pivotal role in the development of certain SARS-CoV-2 variants, such as XA, XD, XF, XE, and XBB, among others. This report delves into the significance of recombination in the evolution of SARS-CoV-2 variants, especially Omicron sublineages, underscoring the necessity for continuous surveillance of the SARS-CoV-2 genome to identify newly emerged recombinant variants.

27 January 2025 in Virus Evolution
Verified
Journal Article
Open access
EBEmanuele Cristina Gustani Buss
Emanuele Cristina Gustani Buss
MSMostafa Salehi-Vaziri
Mostafa Salehi-Vaziri
PLPhilippe Lemey
Philippe Lemey
MTMarijn Thijssen
Marijn Thijssen
ZFZahra Fereydouni
Zahra Fereydouni
AMAli Maleki
Ali Maleki
Understanding the dispersal patterns of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) lineages is crucial to public health decision-making, especially in countries with limited access to viral genomic sequencing. This study provides a comprehensive epidemiological and phylodynamic perspective on SARS-CoV-2 lineage dispersal in Iran from February 2020 to July 2022. We explored the genomic epidemiology of SARS-CoV-2 combining 1281 genome sequences with spatial data in a phylogeographic framework. Our analyses shed light on multiple international imports seeding subsequent waves and on domestic dispersal dynamics. Lineage B.4 was identified to have been circulating in Iran, 29 days (95% highest probability density interval: 21–47) before non-pharmaceutical interventions were implemented. The importation dynamics throughout subsequent waves were primarily driven from the country or region where the variant was first reported and gradually shifted to other regions. At the national level, Tehran was the main source of dissemination across the country. Our study highlights the crucial role of continuous genomic surveillance and international collaboration for future pandemic preparedness and efforts to control viral transmission.

30 September 2024 in The Journal of Infection in Developing Countries
Verified
Journal Article
Open access
PDF file
AMAli Maleki
Ali Maleki
AAArash Arashkia
Arash Arashkia
MPMohammad Hassan Pouriayevali
Mohammad Hassan Pouriayevali
TJTahmineh Jalali
Tahmineh Jalali
MTMahsa Tavakoli
Mahsa Tavakoli
MRMahdi Rohani
Mahdi Rohani
Introduction: The unexpected outbreak of human Mpox infection beginning in some European countries that were non-endemic for Mpox stunned the world during the Coronavirus Disease 2019 (COVID-19) pandemic in May 2022. The re-emerging Mpox outbreak, which has a greater capacity for human-to-human transmission, was mainly due to traveling. In this paper, we describe the first case of the disease was observed in an Iranian woman infected by her husband who had a history of traveling to Canada. Case Report: The 34-year-old woman had flu-like syndrome with some skin rashes on her hand, finger, and arm. No antivirals were prescribed in this case, and supportive care was used to help her recover. RT-PCR and Sanger sequencing were used to analyze the sample from the oropharyngeal swab and the rash, and the results confirmed the Mpox infection. Conclusions: The risk of infectious disease outbreaks after COVID-19, such as Mpox, is of great importance, and health systems should be vigilant for timely identification and preparedness.